GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » OliX Pharmaceuticals Inc (XKRX:226950) » Definitions » Revenue per Share

OliX Pharmaceuticals (XKRX:226950) Revenue per Share : ₩347.75 (TTM As of Mar. 2025)


View and export this data going back to 2018. Start your Free Trial

What is OliX Pharmaceuticals Revenue per Share?

OliX Pharmaceuticals's revenue per share for the three months ended in Mar. 2025 was ₩52.18. OliX Pharmaceuticals's revenue per share for the trailing twelve months (TTM) ended in Mar. 2025 was ₩347.75.

Warning Sign:

OliX Pharmaceuticals Inc revenue growth has slowed down over the past 12 months.

During the past 12 months, the average Revenue Per Share Growth Rate of OliX Pharmaceuticals was -65.60% per year. During the past 3 years, the average Revenue Per Share Growth Rate was 7.90% per year. During the past 5 years, the average Revenue Per Share Growth Rate was 45.90% per year. During the past 10 years, the average Revenue Per Share Growth Rate was 24.40% per year. Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get other companies' revenue growth rate.

The historical rank and industry rank for OliX Pharmaceuticals's Revenue per Share or its related term are showing as below:

XKRX:226950' s 3-Year Revenue Growth Rate Range Over the Past 10 Years
Min: -53.6   Med: 54.55   Max: 117.6
Current: 7.9

During the past 11 years, OliX Pharmaceuticals's highest 3-Year average Revenue Per Share Growth Rate was 117.60% per year. The lowest was -53.60% per year. And the median was 54.55% per year.

XKRX:226950's 3-Year Revenue Growth Rate is ranked better than
59.7% of 789 companies
in the Biotechnology industry
Industry Median: 0.9 vs XKRX:226950: 7.90

OliX Pharmaceuticals Revenue per Share Historical Data

The historical data trend for OliX Pharmaceuticals's Revenue per Share can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

OliX Pharmaceuticals Revenue per Share Chart

OliX Pharmaceuticals Annual Data
Trend Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24
Revenue per Share
Get a 7-Day Free Trial Premium Member Only Premium Member Only 188.13 268.08 680.32 1,182.80 337.06

OliX Pharmaceuticals Quarterly Data
Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25
Revenue per Share Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 46.81 277.38 15.60 2.59 52.18

Competitive Comparison of OliX Pharmaceuticals's Revenue per Share

For the Biotechnology subindustry, OliX Pharmaceuticals's PS Ratio, along with its competitors' market caps and PS Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


OliX Pharmaceuticals's PS Ratio Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, OliX Pharmaceuticals's PS Ratio distribution charts can be found below:

* The bar in red indicates where OliX Pharmaceuticals's PS Ratio falls into.


;
;

OliX Pharmaceuticals Revenue per Share Calculation

Revenue per Share is the amount of Revenue per outstanding share of the company's stock.

Also referred as sales, revenue is income that a company receives from its normal business activities, usually from the sale of goods and services to customers. Revenue is often referred to as the "top line" due to its position on the income statement at the very top.

OliX Pharmaceuticals's Revenue Per Share for the fiscal year that ended in Dec. 2024 is calculated as

Revenue Per Share (A: Dec. 2024 )=Revenue (A: Dec. 2024 )/Shares Outstanding (Diluted Average) (A: Dec. 2024 )
=5677.152/16.843
=337.06

OliX Pharmaceuticals's Revenue Per Share for the quarter that ended in Mar. 2025 is calculated as

Revenue Per Share (Q: Mar. 2025 )=Revenue (Q: Mar. 2025 )/Shares Outstanding (Diluted Average) (Q: Mar. 2025 )
=976.552/18.714
=52.18

Revenue per Share for the trailing twelve months (TTM) ended in Mar. 2025 adds up the quarterly data reported by the company within the most recent 12 months, which was ₩347.75

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


OliX Pharmaceuticals  (XKRX:226950) Revenue per Share Explanation

In ranking the predictability, companies with more consistent revenue and earnings growth are ranked high with predictability.

Peter Lynch categorized companies according to their revenue growth:

Slow Grower: Inflation < 10-Year Revenue Growth Rate < 10%:
Stalwart: 10% < 10-Year Revenue Growth Rate < 20%:
Fast Grower: 10-Year Revenue Growth Rate > 20%:

His favorite companies are stalwart, those growing between 10-20% a year.

Companies in cyclical industries may see their revenue fluctuate wildly in good years and bad years.


Be Aware

Revenue can be manipulated by changing the way how revenue is booked. Companies may book sales before the payment is received, or before the revenue is fully earned. These will be added to balance sheet items such as account payable or account receivables.


OliX Pharmaceuticals Revenue per Share Related Terms

Thank you for viewing the detailed overview of OliX Pharmaceuticals's Revenue per Share provided by GuruFocus.com. Please click on the following links to see related term pages.


OliX Pharmaceuticals Business Description

Traded in Other Exchanges
N/A
Address
No. 1014 Gwanggyo Ace Tower 1, Daehak 4-ro, Yeongtong-gu, Gyeonggi, Suwon, KOR, 16226
OliX Pharmaceuticals Inc is a clinical stage biotechnology company. It is engaged in developing RNA interference (RNAi) technology therapeutics for dermal, ophthalmic and pulmonary diseases. The company's pipeline products include OLX101, OLX201, OLX301, OLX102, and others.

OliX Pharmaceuticals Headlines

No Headlines